According to the research report titled ‘Global Acute Myeloid Leukemia Market Analysis, 2020’, available with Market Study Report, global acute myeloid leukemia market is expected to register a CAGR of 13% between 2020 and 2025.
 

As per test type, global acute myeloid leukemia industry is split into lumbar puncture, imaging, bone marrow, and blood. The imaging segment is further classified into ultrasound, MRI scans, CT scans, and X-rays.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2822567/
 

In terms of medication type, the market is divided into radiation therapy, targeted therapies, stem cell transportation, chemotherapy, and others. The targeted therapies segment is further bifurcated into hedgehog pathway inhibitor, BCL-2 inhibitor, Gemtuzumab ozogamicin, IDH inhibitors, and FLT3 inhibitors. The chemotherapy segment is also categorized into etoposide, cladribine, anthracycline, and cytarabine.
 

By route of administration, the overall industry is fragmented into oral, intravenous, and others. The report states that global acute myeloid leukemia industry size from intravenous segment is predicted to expand significantly during the forecast period. Widespread adoption of intravenous injection systems over conventional chemotherapy sessions is fueling the segmental share.
 

The end-user scope of the market consists of laboratories, hospitality & specialty centers, and others. According to the report, hospitals & specialty center accounted for the largest market share in 2019 and is likely to generate lucrative returns in the ensuing years. High occurrence of AML across the globe and growing elderly population are facilitating the overall business scenario.
 

Global acute myeloid leukemia industry size from laboratories segment is also likely to witness a healthy CAGR through 2025, primarily due to rising R&D activities and growing demand for targeted therapy drugs.
 

Sunesis Pharmaceuticals Inc., Daiichi Sankyo Co. Ltd., Bayer Corp., Johnson & Johnson, Genmab A/S, Celgene Corp., Sanofi Genzyme, Novartis AG, Pfizer Inc., and Bristol Myers Squibb are some of the key competitors in global acute myeloid leukemia market.